ORIC Pharmaceuticals (ORIC) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$0.33
- EPS estimate
- −$0.41
- EPS surprise
- +18.56%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Nov 13, 2025
ORIC Pharmaceuticals reported Q3 2025 results on November 13, 2025. The company posted a loss of $0.33 per share, narrower than the $0.41 loss analysts expected, an 18.56% beat. No revenue or revenue estimate was given. A year earlier, in Q3 2024, the loss was $0.49 per share, so the loss narrowed by about a third.
Every quarter in the table is a loss, and none shows revenue. Full-year losses were $2.07 per share in 2021, $2.25 in 2022, $1.96 in 2023 and $1.82 in 2024. The first three quarters of 2025 added up to a loss of $1.22, compared with $1.31 for the same period of 2024. The Q3 2025 loss was the smallest in the table, while the largest was $0.84 in Q4 2020, the oldest row. ORIC beat the EPS estimate in 10 of the last 20 quarters and missed in the other 10.
The table has no results after Q3 2025. In past years, Q4 results arrived between February 18 and March 23. The next row will show whether the narrower loss seen in Q3 2025 carried into the end of the year.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 13, 2025 | −$0.41 | −$0.33 | +18.56% | $0.00 | SEC |
| Q2 2025 | Aug 12, 2025 | −$0.44 | −$0.47 | −6.09% | $0.00 | SEC |
| Q1 2025 | May 5, 2025 | −$0.51 | −$0.42 | +17.82% | $0.00 | SEC |
| Q4 2024 | Feb 18, 2025 | −$0.50 | −$0.51 | −1.92% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.48 | −$0.49 | −2.47% | $0.00 | SEC |
| Q2 2024 | Aug 12, 2024 | −$0.41 | −$0.45 | −9.12% | $0.00 | SEC |
| Q1 2024 | May 6, 2024 | −$0.43 | −$0.37 | +13.79% | $0.00 | SEC |
| Q4 2023 | Mar 11, 2024 | −$0.48 | −$0.49 | −2.62% | $0.00 | SEC |
| Q3 2023 | Nov 6, 2023 | −$0.46 | −$0.44 | +4.80% | $0.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.57 | −$0.50 | +12.11% | $0.00 | SEC |
| Q1 2023 | May 8, 2023 | −$0.54 | −$0.53 | +1.92% | $0.00 | SEC |
| Q4 2022 | Mar 16, 2023 | −$0.55 | −$0.52 | +5.11% | $0.00 | SEC |
| Q3 2022 | Nov 7, 2022 | −$0.55 | −$0.63 | −13.92% | $0.00 | SEC |
| Q2 2022 | Aug 11, 2022 | −$0.60 | −$0.51 | +15.01% | $0.00 | SEC |
| Q1 2022 | May 9, 2022 | −$0.57 | −$0.59 | −3.85% | $0.00 | SEC |
| Q4 2021 | Mar 21, 2022 | −$0.57 | −$0.58 | −2.58% | $0.00 | SEC |
| Q3 2021 | Nov 8, 2021 | −$0.58 | −$0.47 | +19.30% | $0.00 | SEC |
| Q2 2021 | Aug 10, 2021 | −$0.49 | −$0.57 | −15.76% | $0.00 | SEC |
| Q1 2021 | May 6, 2021 | −$0.48 | −$0.45 | +6.74% | $0.00 | SEC |
| Q4 2020 | Mar 23, 2021 | −$0.41 | −$0.84 | −104.48% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did ORIC Pharmaceuticals (ORIC) last report earnings?
ORIC Pharmaceuticals last reported on Nov 13, 2025, covering fiscal Q3 2025.
Did ORIC beat earnings estimates?
Yes. ORIC Pharmaceuticals reported EPS of −$0.33 for Q3 2025 against a −$0.41 estimate — a 18.56% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.